Chimerix receives extended patent life for potential HBV analog

Chimerix Inc., a licensing partner of ContraVir Pharmaceuticals, received a Notice of Allowance from the United States Patent and Trademark Office for an extended patent life on its “Nucleoside Phosphonate Salts” patent, which includes CMX157, an analog intended for the treatment of hepatitis B virus infection, according to a press release.

CMX157 is a novel lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of Viread (tenofovir diphosphate, ContraVir), an antiviral agent, currently being developed for the treatment of HBV. It decreases levels of tenofovir, lowering systemic exposure and reduces the potential for renal side effects, according to the ContraVir website.

The patent covers the composition of matter for CMX157 and will extend ContraVir’s intellectual property protection of the analog through at least 2031, according to the release. 

Read more....

Labels: , ,